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The Detection of Bacteria and Matrix Proteins on
Clinically Benign and Pathologic Implants
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Background: Bacterial contamination of breast implants causes infection, can lead
to capsular contracture, and is implicated in breast implant-associated anaplastic
large cell lymphoma. Bacteria, however, also colonize clinically benign breast implants and little is known about the biologic signals that trigger the switch from a
benign to pathologic state.
Methods: Explanted smooth as well as Biocell and Siltex textured breast implants
associated with clinically normal and pathologic conditions were analyzed in this
observational study. Immunofluorescence and bacterial culture techniques were
performed. To avoid sampling bias, implant surfaces >25 sq cm were analyzed.
Results: Bacteria were detected on 9 of 22 clinically normal explanted devices or
periprosthetic capsules, including 40% of Biocell tissue expanders and 75% of Biocell textured implants. Staphylococcus epidermidis was identified in 67% of the bacteria-positive capsular contractures. Fibrinogen was present on 17 of 18, and collagen
on 13 of 18 analyzed breast implants. S. epidermidis co-localized with collagen, while
group B streptococci and Klebsiella pneumoniae co-localized with fibrinogen.
Conclusions: Bacteria are often detectable on clinically benign breast implants when
a multimodal approach is applied to a substantial proportion of the device surface to
avoid sampling bias. The impact of bacteria on breast implant pathology should be
studied in the presence of an adequate negative control group to account for clinically benign bacteria. Disruption of the interaction of bacteria with matrix proteins
coating the surface of breast implants may represent a nonantibiotic strategy for the
prevention of breast implant bacterial contamination. (Plast Reconstr Surg Glob Open
2019;7:e2037; doi: 10.1097/GOX.0000000000002037; Published online 8 February 2019.)

INTRODUCTION

Bacterial contamination of breast implants can cause infection,1 capsular contracture (CC),2–4 and has been linked
to breast implant-associated anaplastic large cell lymphoma
(BIA-ALCL).5 Bacteria can also be identified on clinically benign breast implants, however, as they indefinitely abut paFrom the *Department of Molecular Microbiology; †Department of
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renchymal tissue laden with a diverse array of microbes.6–10
Staphylococcus epidermidis is the most common bacterium
found on both pathologic and nonpathologic implants, yet
why complications manifest in some women and not others remains unknown.11 To establish the impact of bacterial
contamination, including differing bacterial species, strains,
abundance, or virulence factors, on breast implant pathology, detailed characterization of bacteria on clinically benign
breast implants is needed to establish a negative control
against which pathology can be compared.
The majority of bacterial infections of medical devices
are associated with biofilms. Hallmarks of these infecDisclosure: This study was funded by an investigatorinitiated grant from Allergan Inc. to Dr. Myckatyn (IIT2017-10074). Dr. Myckatyn has received grant funding,
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tions include increased resistance to antibiotics and the
host immune system, resulting in chronic infection, treatment failure, and often surgical intervention.12 For breast
implants bacterial biofilm formation is a major concern.
There is a large unmet need to understand the mechanisms by which bacteria colonize breast implants to form
biofilms to develop effective drugs that can eradicate
biofilm-associated infections. The extent to which bacteria become associated with breast implants is influenced
by the surface characteristics of the device.13–15 Textured
devices, whose contoured surfaces have increased surface
area available for bacterial colonization, harbor significantly more bacteria than do smooth breast implant surfaces.16 However, recent studies show that medical devices
become coated with host proteins that can be exploited by
bacterial pathogens for colonization and biofilm formation.11,17 For example, Staphylococcus aureus, which causes
the majority of implant-associated infections (IAI), utilizes
a fibrinogen binding adhesin to colonize devices that become coated with fibrinogen, a common occurrence after
placement of most kinds of medical devices.18,19 For breast
prostheses, additional host ligands are deposited on the
devices in the form of a collagen-rich capsule and this
likely facilitates bacterial colonization.20,21 A granular understanding of the host-pathogen interactions that lead to
breast implant colonization and the biological signals that
trigger the switch from a benign to a pathologic state will
inform future strategies to optimize breast implant design
and establish antibiotic-sparing therapies that prevent
problematic bacterial contamination.19,22–25
The purpose of this observational study is 2-fold: (1) we
examined the extent of which bacteria were associated with
a series of explanted breast prostheses, with different surface
characteristics, obtained from normal and pathologic clinical scenarios and used immunofluorescence techniques to
characterize the bacteria associated with the devices; and
(2) we evaluate, for the first time, matrix protein deposition on the breast device surface to determine the potential
repertoire of available bacterial binding ligands. Characterization of bacterial binding mechanisms to breast implants
may lead to the development of nonantibiotic antibacterial
therapeutics for downstream clinical translation.

METHODS
Study Population

Cosmetic or reconstructive breast prostheses, either
implants or tissue expanders (TE), explanted between
March 2017 and March 2018 were analyzed under protocol #201703063 at the Washington University School of
Medicine. We identified patients with CC, double capsules,
seroma, and infection. Benign breast prostheses consisted
of TE removed at the time of planned device exchange
as well as the contralateral breast implant in patients with
unilateral pathology where both devices were explanted.
Breast prostheses and capsules were sharply removed using sterile technique, the surface between capsule and
implant was marked with a suture, and samples were sectioned and immediately placed in a sterile container. In all
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cases, the entire breast prosthesis was removed, while the
entire capsule was removed in cases of CC and double capsules, while the submuscular capsule was entirely removed
but the acellular dermal matrix sling maintained in cases
of submuscular TEs. In this manner, >25 sq cm of capsule
and implant surface was made available for analysis. Device type was confirmed to be consistent with the medical
record. Duration of implantation, device type, and clinical
presentation were recorded.
Bacterial Culture and Identification

Explanted devices were divided into 3 sections, the largest section (>25 sq cm) was fixed for immunofluorescence
staining and the 2 smaller pieces (~4–25 sq mm) were cultured for bacterial growth. One piece was sonicated for 10
minutes in phosphate buffered saline, plated on the rich
media Brain Heart Infusion agar, and grown aerobically
and anerobically at 37°C for 48 hours. Individual bacterial
species were evaluated for colony size, morphology, color,
and bacterial load. The second piece was submerged in
BHI and grown for 48 hours at 37°C. Cultures with visible microbial growth were restreaked onto BHI agar for
single colonies. A representative isolate of each bacterial
species was selected for identification via 16S sequencing,
as described previously.18
Immunofluorescence Staining

Immunofluorescence staining was performed as previously described.18 Briefly, the largest piece of the patient
device was fixed, blocked, washed, and incubated with
primary antibodies. Devices were then washed and incubated with secondary antibodies, which were then washed,
dried, and imaged. All antibodies were tested against each
isolated bacterial species to determine the optimal concentration for immunofluorescence detection. Infrared
signal was examined using the Odyssey Imaging System
(LI-COR Biosciences, Lincoln, Nebraska). Controls for
auto-fluorescence included small pieces of each respective device in the absence of primary antibody were performed.

RESULTS
Study Population

Twenty-two clinically benign and 18 clinically pathologic breast prostheses were explanted from 33 women.
Half of the breast prostheses placed were for reconstructive cases and the other half were for cosmetic purposes.
Duration of implantation ranged from 3 months for
some TEs to 540 months for severely contracted smooth,
shaped, saline filled Dow Corning breast implants. Pocket
irrigation with 50% Betadine26 was utilized in the TE cases,
but this information was not reliably available for the other implants collected.
Bacteria Cultured from Benign Breast Implants

Patient samples were cultured to determine the bacterial abundance (Table 1), and 16S sequencing was utilized
to identify the species (Fig. 1 and Supplemental Digital
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Table 1. Bacterial Load Recovered from Clinically Normal
and Complicated Patient Devices
Breast Implant Study Bacterial Load
Variable
Clinically
normal

Patient
No.

Material

CFU

2

Expander

3

Expander

4

Expander

2.0 x 10^0
3.0 x 10^0
3.0 x 10^0
1.3 x 10^1
5.9 x 10^1
3.5 x 10^1

Capsule

Clinically complicated

7

Implant

23
22
25

Implant
Implant
Capsule

27
32

Capsule
Left

1.69 x 10^3
2.0 x 10^1
3.1 x 10^2
2.0 x 10^1
1 x 10^0
1 x 10^0
4.0 x 10^0
1 x 10^0
1.0 x 10^0
2.3 x 10^1
5.0 x 10^0
1.3 x 10^1

Colony
Identity
M. luteus
S. epidermidis
CNS
S. epidermidis
CNS
Pseudomonas
aeruginosa
K. pneumoniae
E. faecalis
P. aeruginosa
CNS
S. haemolyticus
S. hominis
S. cohnii
S. epidermidis
S. epidermidis
CNS
S. epidermidis
Staphylococcus
epidermidis

CFU, colony forming units.

Content 1) colonizing uncomplicated devices (see figure,
Supplemental Digital Content 1, which displays presence,
absence, and species of bacteria identified on breast implants explanted from women in the absence of clinical
pathology. Results from analyses for bacteria from TEs,
permanent breast implants (I), capsules (CAP), http://
links.lww.com/PRSGO/A930). Bacteria were cultured
from 9 of 22 clinically normal explanted devices or periprosthetic capsules, including 6 of 15 (40%) Biocell TEs
and 3 of 4 (75%) Biocell textured implants. In instances
where bacteria were recovered, more than one species was
identified in 6 of 9 breasts (Supplemental Digital Content
1). Only Gram-positive bacteria, and specifically coagulasenegative staphylococci (CNS), were detected on clinically
normal breast implants. In contrast, clinically normal TE
were colonized by a broader array of both Gram-positive
and Gram-negative bacteria. CNS, Klebsiella pneumoniae,
Pseudomonas aeruginosa, and Enterobacter, were recovered
from 4 Biocell textured TE implanted for 124, 157, 180,
and 372 days (Supplemental Digital Content 1). Bacteria
were not detected on the 3 clinically normal saline and
Siltex textured breast implants evaluated (Fig. 1 and Supplemental Digital Content 1). Additionally, while capsular
tissue was not routinely harvested for all specimens, there
were 2 instances, one with a TE and one with an implant,
where bacteria were retrieved from the prosthesis but not
the capsule (Supplemental Digital Content 1).
Bacteria Cultured from Pathologic Breast Implants

Clinically complicated samples were cultured and
bacterial abundance was assessed (Table 1) and species
colonizing pathologic prostheses were determined via
16S sequencing (Fig. 1 and Supplemental Digital Content 1). CCs were noted in 12 breast prostheses collected
from 8 women (Fig. 1 and Supplemental Digital Content
2) and S. epidermidis was identified in the majority (67%)

of these cases (see figure, Supplemental Digital Content
2, which displays presence, absence, and species of bacteria identified on breast implants explanted from women
in the absence of clinical pathology. Pathology categorized as CC, double capsule without seroma (seroma (-)
ve), double capsule with seroma (seroma (+)ve), or infection requiring explantation, http://links.lww.com/
PRSGO/A990). Other Gram-positive bacteria, including
other CNS, were found colonizing the rest (Supplemental Digital Content 2). Smooth-surface and Siltex and
Biocell textured devices (both saline and silicone) were
represented in the CCs analyzed (Fig. 1). Bacteria were
inconsistently identified in smooth and textured devices
complicated by CC (Fig. 1). Double capsules—defined as
2 distinct capsules between the device and the soft-tissue
space with 1 capsule tenaciously adherent to the device
surface—were exclusively identified in patients with Biocell textured prostheses (Fig. 1). CNS were identified in
2 of the 5 double capsules with or without seroma (Fig. 1
and Supplemental Digital Content 2). One TE was explanted for infection, and CNS was isolated (Fig. 1 and
Supplemental Digital Content 2). Interestingly, the microbes isolated from the complicated prostheses were
exclusively Gram-positive bacteria.
Matrix Protein Deposition on Breast Implants

Complicated (n = 5) and normal (n = 13) devices without any detectable bacteria were immunofluorescently
stained for the presence of host proteins, including fibrinogen, a protein known to be deposited on other medical
devices,18,22,27 and collagen type I and type III, proteins that
make up the implant capsule.21,28,29 Fibrinogen was present
on 5/5 and 12/13 clinically complicated and normal devices
(Table 2 and Fig. 2). Collagen was detected on 4/5 and 9/13
clinically complicated and normal devices. All analyzed textured devices, including 14 Biocell and 2 Siltex, were coated
with fibrinogen. Smooth surfaced breast implants4 included
1 that lacked matrix protein deposition, 1 coated with fibrinogen, and 2 coated with fibrinogen and collagen.
Bacteria Co-localize with Deposited Matrix Proteins

Breast prostheses with detectable bacteria16 were immunofluorescently stained with commercially available
antibodies for the respective microbe (antibodies were
not available for Micrococcus, Bacillus, or Exiguobacterium).
S. epidermidis was detected on all devices from which the
bacteria were isolated (Table 3). Additionally, since staphylococcal-collagen interactions have been implicated in
breast IAI,11 we simultaneously stained the samples for collagen. S. epidermidis predominantly co-localized with collagen (Tables 4, 5, Fig. 3). Furthermore, group B strep
was detected on the device from patient 9 (Supplemental
Digital Content 2 and Fig. 3) and K. pneumoniae was detected on the prostheses from patient 23 (Supplemental
Digital Content 2 and Fig. 3). Interestingly, we found that
group B Strep and K. pneumoniae co-localized with fibrinogen (Table 4). Bacteria were not detected on the other 10
devices via immunofluorescence staining. Overall, of the
bacteria that could be detected on both clinically normal
and pathologic Biocell textured and smooth surfaced im-
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Fig. 1. Schematic categorization of study implants by presence or absence of pathology, presence or absence of implant or capsular bacteria, and implant type. Pathology includes CC, double capsule with or without intervening seroma, and infection requiring explantation.

plants, all were found to co-localize with matrix proteins
(Tables 4, 5, Fig. 3).

Table 2. Clinically Normal Breast Implants without
Detectable Bacteria Stained for Deposited Fibrinogen
and Collagen
Patient
No.
1
6
8
11
12
13
17
18
19
20
21
23
24

4

DISCUSSION

Implant

Texturing
(+/-)

Fibrinogen

Collagen

I
TE
TE
TE
TE
TE
I
I
TE
TE
TE
TE
I

Smooth
Biocell texture
Biocell texture
Biocell texture
Biocell texture
Biocell texture
Siltex texture
Smooth
Biocell texture
Biocell texture
Biocell texture
Biocell texture
Smooth

+
+
+
+
+
+
+
˗
+
+
+
+
+

˗
+
+
˗
+
+
+
˗
+
˗
+
+
+

Bacteria cause IAI,1 have a role in CC,2,3,30–32 and may
play a role in the etiology of BIA-ALCL5; however, the
microbial species responsible and the host-pathogen
interactions that result in these diverse complications
are still being investigated. We have previously shown
that the predominant Gram-positive and Gram-negative bacterial causes of breast IAI and explantation
are S. aureus and P. aeruginosa, respectively.1 Ralstonia
pickettii has also been identified in a disproportionately high percentage of breast implants from patients
with BIA-ALCL.5 Additionally, while there is a growing body of evidence implicating bacterial coloniza-
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Fig. 2. Representative images of clinically normal and clinically complicated breast implants immunofluorescently stained for fibrinogen and collagen. All devices imaged had no culturable bacteria. Staining revealed collagen (Cn) and fibrinogen (Fg) were present on the majority of clinically uncomplicated
(A and B) and clinically complicated (C and D) patient devices. Controls are implant pieces treated the
same but without primary antibody. Commercially available primary antibodies: goat antifibrinogen
(Cat # F8512); rabbit anticollagen (Cat. #234169, Calbiochem).

Table 3. Breast Implants with Pathology without
Detectable Bacteria Stained for Deposited Fibrinogen and
Collagen
Patient
No.

Pathology

Implant Surface Fibrinogen Collagen

10

CC

TE

16

CC

I

31
15
33

CC
Double capsule,
Seroma (˗)ve
Double capsule,
Seroma (+)ve

I
TE
I

Biocell
texture
Siltex
texture
Smooth
Biocell
texture
Biocell
texture

+

˗

+

+

+
+

+
+

+

+

Table 4. Bacteria Can Be Detected on Clinically Normal
Breast Implants and Bacteria Co-localizes with Host Matrix
Protein Deposition
Patient
No.
2
3
4
5
9
23

Implant/
Surface
TE/Biocell
TE/Biocell
TE/Biocell
TE/Biocell
Implant-Biocell
TE/Biocell

Host Protein
Detected

Microbe
Detected

Co-localize
(+/˗)

Collagen
Collagen
Collagen
Collagen
Fibrinogen
Fibrinogen

S. epi
S. epi
CNS
CNS
GBS
K. pneum

+
+
+
+
+
+

tion of devices in the development of CC, including a
strong correlation between Baker grade and positive
reduction in
breast implant and TE cultures3 and a 
CC rates after breast implant placement with the use

of 
antibiotic pocket irrigation or impregnated mesh
strategies,32–35 these findings are not universally consistent among reports,36,37 and the latter are limited to a
mean of 2 years of follow-up or less.33–35 An elegant swine
model, however, has demonstrated causation between
S. epidermidis infection and CC.2 Together, these studies highlight the need to better understand the hostpathogen interactions that facilitate the development of
pathologic implants in patients, including CC and BIAALCL, to implement truly effective interventions.
To understand how bacteria influence the development of breast implant-associated complications, it is
critical to know which bacteria are present in a clinically
benign scenario. However, data from this “negative control” group are scant, as evaluating normal breast implant
colonization is challenging since it requires assessing
either temporary TE38 or permanent implants explanted at the time of less common revision surgery due to
malposition or when managing pathology on the contralateral side. Of the few small studies that address this question, Pajkos et al.4 identified bacteria in 1 of 8 (12.5%)
clinically benign breast implants, Rieger et al.3 identified
bacteria in 4 of 21 (19%) patients with Baker grade I and
II capsules, and Hu et al.5 identified 7.6 × 105 bacteria/mg
tissue in 3 clinically normal breast implants. Significantly,
more bacteria were detected on pathologic implants than
uncomplicated ones in these studies, suggesting bacterial
abundance impacts the development of complications.
The presence of bacteria on benign implants, though, requires further study to determine whether bacterial spe-
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Table 5. Bacteria Can Be Detected on Breast Implants with Pathology and Bacteria Co-localizes with Host Collagen
Deposited
Patient No.

Implant/
Surface

22
25
26

Implant/Biocell
TE/Biocell
Implant/Biocell

29

Implant/smooth

30

Implant/Biocell

Pathology
Double capsule,
Seroma (˗)ve
Infection
Double capsule,
Seroma (+)ve
Double capsule,
Seroma (+)ve
CC

Host Protein
Detected

Microbe
Detected

Co-localize
(+/˗)

Collagen
Collagen
Collagen

S. epi
CNS
CNS

+
+
+

Collagen

CNS

+

Collagen

S. epi

+

Fig. 3. Representative images of devices immunofluorescently stained for cultured bacteria and host
proteins. A, Group B streptococcus (GBS) was cultured from the Biocell-textured silicone breast implant
of patient 9, which was clinically normal. GBS was detected via immunofluorescence staining and it colocalized with the deposited host protein fibrinogen (Fg). Staphylococcus epidermidis (SE) was cultured
from patient 22’s Biocell-textured silicone implant, which was clinically complicated by a double capsule without seroma. SE was visible on the device and co-localized with collagen (Cn). K. pneumoniae
(KP) and SE were cultured from patients 23’s Biocell-textured TE, which was clinically normal. KP (C) and
SE (D) were both visible on the device and co-localized with deposited Fg and Cn, respectively. Controls
were pieces of each device treated the same, but without primary antibody. Commercially available
primary antibodies: goat antifibrinogen (Cat # F8512); rabbit anticollagen (Cat. #234169, Calbiochem);
mouse anti-S. epidermidis (Cat. # MA1-35788, ThermoFisher Scientific); rabbit anti-Pseudomonas (Cat. #
ab68538, Abcam); rabbit anti-Protein A (for S. aureus) (P3775, Sigma-Aldrich); rabbit antienterococcus
(Cat. # PA1-73120); rabbit anti-Klebsiella,58 and rabbit antigroup B streptococcus.22,59 Secondary antibodies: IRDye 800CW donkey antigoat, IRDye 800LT donkey antimouse, and IRDye 680LT donkey antirabbit
(LI-COR Biosciences).

cies or strains, virulence factor production, or interactions
with other bacteria or the host contribute to the development of complications.19,24,39–41
While this study is not adequately designed or powered to compare the bacterial abundance between clinically normal and complicated breast implants, it does
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provide important insights into the potential bacterial
reservoir on uncomplicated devices. In this study, we detected bacteria in 41% of the clinically normal breast implants and/or surrounding capsules analyzed—a higher
proportion of bacteria-positive, normal breast prostheses
than previous reports.3–5 This is likely due to our combin-
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ing standard sonication and plating, similar to previous
studies, with liquid culturing techniques, to detect low
colonization levels and/or bacteria firmly adherent to the
implant. Of the clinically normal implants that were bacteria-positive, all had a Biocell-textured surface and were
colonized exclusively by Gram-positive bacteria, with CNS
the chief microorganism identified. For clinically normal TE, all colonized devices also had Biocell-textured
surfaces; however, Gram-negative bacteria, including K.
pneumoniae and P. aeruginosa, were found in addition to
Gram-positive microorganisms. The wider array of bacteria present on TE may be due to the fact that the implant
reconstruction paradigm differs significantly from aesthetic breast augmentation, with the traumatic dispersion
of parenchymal and ductal bacteria from the breast and
skin microbiome during mastectomy and reconstruction,
longer operative times, and the potential for disease- or
chemotherapy-induced immunosuppression.1,42 Recognizing the greater likelihood for bacterial contamination
following TE breast reconstruction,42 a higher incidence
of bacterial contamination with a more diverse group of
microbes is not unexpected. Notably, the routine use of
betadine irrigation of the skin and postmastectomy pocket before insertion of a TE with acellular dermal matrix
may have been sufficient to reduce the contaminating
bacteria below a clinically problematic threshold in these
patients.13,26 Interestingly, similarly to what we found for
normal implants, only Gram-positive bacteria, and primarily CNS, were found colonizing CC (50%) and double capsule (40%) specimens. While we cannot discount
that some of the patients with colonized, clinically normal
devices would eventually go on to develop complications
like infection or CC, future studies elucidating the hostpathogen interactions that lead to pathologic implants
will be critical for understanding why some women with
colonized implants develop complications while others
do not.
The presence of CNS, which are known skin colonizers, on both pathologic and benign implants supports
the dogma that breast prosthesis contamination primarily
occurs through contact with the skin microbiota during
placement. However, even if skin contact can be minimized,43,44 breast implants are still susceptible to bacteria
that reside in the breast parenchyma, which also contain
CNS, among other Gram-positive bacteria.6–10 Thus, the
breast represents a clean-contaminated surgical site.9 Importantly, the breast microbiome has greater microbial
diversity than the skin,6 and is formed and evolved over
time through the translocation of bacteria through mucosal membranes of the gut, oropharynx, and urogenital
tract.7,45,46 Recent evidence suggests that the composition
of the breast microbiome varies based on depth of biopsy,
suggesting the important contributions of the nipple and
skin microbiome to bacteria within the breast.10 Given the
proximity of a breast implant to the colonized breast parenchyma, there is ample opportunity, even years past the
time of initial device insertion, for bacteria to contact the
implant surface and/or capsule. Thus, it is reasonable to
expect that the bacteria contaminating implants is similar
to the breast parenchyma microbiome because parenchy-

mal microbes have the most direct pathway to the implant
surface after placement.
Our previous work detailing the molecular mechanisms that result in catheter-associated urinary tract infections (CAUTI) has provided important insights into the
host-pathogen interactions that facilitate disease and may
lead to the development of therapeutics to treat these
recalcitrant infections.18 This work showed that fibrinogen, which is recruited to the bladder following catheterinduced damage to the urothelium, is deposited on the
urinary catheter surface and provides a critical binding
substrate for Enterococcus faecalis and S. aureus adherence
and biofilm formation.18,22 By developing a vaccine that
specifically blocked the ability of the adhesive tip of the
E. faecalis Ebp pilus to interact with fibrinogen, we could
effectively prevent and treat enterococcal CAUTI in a
mouse model.22 Thus, by identifying bacterial virulence
mechanisms and dissecting the host-pathogen interactions that lead to CAUTI, it may be possible to design and
develop effective therapeutics. Herein, we begin to translate this work to the breast implant paradigm. We found
that fibrinogen was deposited on 17/18 and collagen on
13/18 of the breast implants analyzed in both clinically
normal and abnormal cohorts (Tables 2, 3). Fibrinogen
deposition likely stems from surgical manipulation of the
breast parenchyma, which stimulates inflammation.47,48
Importantly, the deposition of host proteins, including
fibrinogen and collagen, on breast prostheses has important implications for bacterial adherence and infection,
as it is becoming increasingly clear that many bacteria
encode proteins that bind to these factors to facilitate
disease. Notably, we found that CNS co-localized with collagen on explanted breast implants. S. epidermidis elaborates SdrF49 and GehD, which interact with collagen,50
thus providing a potential mechanism for S. epidermidis
breast implant adherence or biofilm formation. Interestingly, K. pneumoniae51 and Group B Strep52 that express pili
that are reported to play an important roles in biofilm formation19,53 co-localized with fibrinogen in our explanted
implants. Together, these data provide important insights
into potential targets for the development of nonantibiotic therapeutics, including small molecule inhibitors or
vaccines that specifically block host-pathogen interactions
that facilitate disease.24,40 Immediate next steps will include further characterization of matrix protein binding
to various breast implant surfaces and the predilection of
particular bacteria to them.

CONCLUSIONS

We readily detected bacteria and matrix protein deposition on the smooth and textured surfaces of clinically
normal and pathologic implants, explanted months to
decades after insertion. Bacteria co-localized with matrix
proteins, thus suggesting bacteria may preferentially adhere to host proteins instead of abiotic surfaces. Future
studies examining bacteria-related breast implant pathology should analyze a sufficient percentage of the implant
surface to avoid sampling bias, and include an adequately
powered control group. Finally, several knowledge gaps in
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the field of breast implant bacteria require further study
including identifying the signals, bacterial, or host, that
trigger the transition from a normal, uncomplicated implant to a pathologic state and the role of matrix proteins,
like collagen and fibrinogen, in implant contamination.
The answers to these questions may lead to the development of novel nonantibiotic therapeutic strategies.
Terence M. Myckatyn, MD, FACS, FRCSC
Plastic and Reconstructive Surgery
Washington University School of Medicine
West County Plastic Surgeons
1020 N. Mason, Ste 110
Saint Louis, MO 63141
Email: myckatyn@wudosis.wustl.edu
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